

Review Article

A Discussion on the Detection and Evaluation of Diabetic Retinopathy

Palak Malhotra¹, Rupinder Kaur²

^{1,2}DAV Institute of Engineering and Technology, Jalandhar, Punjab, India.

I N F O

Corresponding Author:

Palak Malhotra, DAV Institute of Engineering and Technology, Jalandhar, Punjab, India.

E-mail Id:

impalak220@gmail.com

Orcid Id:

<https://orcid.org/0009-0002-9379-4729>

How to cite this article:

Malhotra P, Kaur R. A Discussion on the Detection and Evaluation of Diabetic Retinopathy. *J Adv Res NanoSci NanoTech.* 2023; 5(1): 1-5.

Date of Submission: 2023-02-13

Date of Acceptance: 2023-05-01

A B S T R A C T

Diabetic retinopathy is a leading cause of blindness in the United States. The CDC projects that the rate of DR will increase thrice between the years 2005 and 2050. A paper that provides an overview of current developments in diabetes research as well as their potential implications for therapy. Both the current course of events and potential future developments are considered. Diabetic retinopathy causes the greatest blindness worldwide. Long-term untreated diabetes produces blood glucose swings. It has become a major issue that must be addressed immediately to avoid eyesight loss in working-age people. As quickly as possible. Artificial intelligence-based diagnostic methods have been used to assess diabetic retinopathy severity and establish an initial diagnosis. Early discovery makes treatment simpler, thus eye problems may frequently be prevented. Blood vessels, microaneurysms, exudates, macula, optic discs, and hemorrhages are used to detect diabetic retinopathy in this detailed study. Most clinical research uses fundus cameras to image the retina. Fundus photos are used. This paper discusses diabetes, its incidence, consequences, and artificial intelligence methods for early diabetic retinopathy detection and categorization. Diabetes is also discussed. Machine learning and deep learning are also examined in the study. Transfer learning via generative adversarial networks, domain adaptability, multitask learning, and explainable artificial intelligence in diabetic retinopathy are all being studied. After discussing ophthalmology's potential issues, a list of datasets, screening methods, performance measurements, and biomarkers in diabetic retinopathy is presented, followed by a conclusion on the field's future potential. The author claims no other literature has examined contemporary state-of-the-art procedures using the PRISMA technique and artificial intelligence. Author claims.

Keywords: Artificial Intelligence; Diabetic Retinopathy; Domain Adaptation; Explainable AI; Fundus; OCT

Introduction

The vascular component of DR has been well-recognized since the illness was first described. The first drawings show the retina with hemorrhages, vascular sheaths, and lipid exudates all over it. Histopathological models, such as the study done by Arthur Ballantyne in 1945, have shown that alterations in the capillary wall lead to the development of Diabetic Retinopathy (DR). These results have been verified by these models. Research on endothelial dysfunction and clinical examination with fluorescein angiography helped to solidify the DR paradigm as a vascular illness. As a result, suggestions for the use of photocoagulation or laser treatment to treat retinopathy were made in the early 1960s. At the Airlie House Symposium in 1968, ophthalmologists and diabetic retinopathy researchers met one another for the first time. During this discussion, both the classification system for diabetic retinopathy and the foundation for the subsequent big clinical study were conceived of and developed.

The Diabetic Retinopathy Trial (DRS) and the Early Treatment Diabetic Retinopathy Trial (ETDRS), both of which were carried out in the 1970s and 1980s, respectively, provided evidence that laser treatment is effective in treating eyes that have proliferative retinopathy and macular edema. PRP, or panretinal photocoagulation, was shown by DRS to slow the progression of retinopathy in individuals who had proliferative (neovascular) alterations. According to the ETDRS, "clinically significant macular edema" is defined as well as the fact that focused photocoagulation lowers the risk of vision loss caused by diabetic macular edema. PRP and focused laser therapy became the standard treatment for patients with diabetic retinopathy in the 1980s as a direct consequence of this clinical experiment, and they continue to be utilised in spite of the effectiveness of intravitreal injections today.

In addition to discovering novel targets for the treatment of early DR, research is now being conducted employing nanoparticles to enable medication release in conjunction with other techniques of drug administration (staining). Nanotechnology is now being used in the production of anti-VEGF medications in addition to the development of several novel therapies for inflammation and angiogenesis. Nanoparticles that have been engineered specifically to break through the barrier that separates the blood and the retina allow for greater penetration into the retina.

The results of the UKPDS, which were published in 1998, also provided the first evidence that hypertension had a role in the onset and progression of diabetic problems.

Controlling blood pressure very closely (mean of less than 150/85 mmHg) for 7.5 years resulted in a 34% reduction in the rate of progression to DR. This reduction was seen regardless of how well glycemic control was maintained. Following the publication of these data, numerous further studies were conducted, all of which found that maintaining healthy blood pressure levels lowers one's likelihood of acquiring DR. The incidence of proliferative diabetic retinopathy and/or diabetic macula has reduced, particularly in patients who have type 1 diabetes. This is a result of improved management of blood sugar as well as temperature and pressure, as well as the invention and improvement of diagnostic and treatment procedures throughout the course of time.


The Wisconsin Diabetic Retinopathy Epidemiology Study (WESDR) was conducted from 1980 to 2007 and revealed that the estimated yearly rate of DR development in patients with type 1 diabetes was lowered by 77% over that time period. At the same time, the incidence of blindness diagnosed attributable to diabetic retinopathy was reduced by 57% during that same time period.

Photocoagulation has a number of drawbacks, despite the fact that using a concentrated laser light and Platelet-Rich Plasma (PRP) may lower the risk of vision loss and the development of DR. PRP may result in impaired vision and a diminished ability to see in the dark since lasers are often damaging. In addition, the visual acuity is seldom improved by focused lasers. As a result, there is a need for improved therapy for both the early and late phases of DR.

Additionally, DR was studied as a proxy for significant vascular disease in certain studies. Several other research have all come to the same conclusion: neuroinflammation is an essential factor in the development of DR. Intravitreal steroids are able to effectively improve vision in individuals who have diabetic macular edema; nevertheless, they are also known to increase intraocular pressure, which may lead to the formation of cataracts as well as glaucoma. It has also been hypothesised that administering steroids intravitreally might slow down the pace at which DR develops into big lesions.

The continued production of inflammatory mediators eventually results in the breakdown of the blood-retina barrier, increased vascular permeability and angiogenesis due to the release of cytokines, growth factors, and Vascular Endothelial Growth Factor (VEGF).

This method is still in the process of being perfected and the therapeutic use of DR has not yet reached its full potential.



In order for the treatment of DR in its early phases to become a standard clinical practise, new diagnostic approaches need to be implemented to detect changes before they can be noticed on examination and to track how well the patient is responding to therapy. The use of circulating biomarkers and novel imaging models as clinical indicators and new endpoints in clinical trials is now the subject of research that is being conducted. Cytokines that promote inflammation are mentioned very often as being relevant biomarkers connected with early DR. When z scores are combined, the inflammatory mediators interleukin 6 (IL-6), Tumour Necrosis Factor alpha (TNF-), and C-reactive Protein (CRP) are shown to be related with the development of diabetic retinopathy, nephropathy, and cardiovascular disease.

Additionally, inflammatory and vasoactive mediators that were created locally and quantified in the ocular fluid were shown to be present. For instance, diabetic individuals exhibited elevated levels of Glial Fibrillary Acidic Protein (GFAP) in their humoral fluid, but they did not exhibit any symptoms of either proliferative or non-proliferative

DR when compared to age-matched healthy controls. However, difficulties still exist in identifying DR-specific biomarkers that may be tested in a straightforward and non-invasive manner. Therefore, the development of improved diagnostic tools for early illness has the possibility of being made possible by new approaches that, when paired with a greater knowledge of biomarkers. Imaging of diabetic animals has been demonstrated to be more predictive than imaging of controls, indicating that the combination of imaging methods and biomarkers may one day allow for the early identification of DR.

On the other hand, it is anticipated that the rate of DR would increase by a factor of three over the course of the next decade, and the disease will not be adequately managed by new diagnosis and therapies alone. Models of health care also need revision. Diabetes has to be treated in the same way that there have been recent shifts in the study group for cancer therapy. The link between ophthalmologists, dietitians, social workers, and everyone else engaged in the treatment of patients with diabetes is essential to the utilisation of community resources, as well as to the

improvement of individual patients' health, clean drinking, and medical results. .

These trials treat diabetic macular edema. In addition, the development of DR was inhibited in 25-30% of eyes that were treated with anti-VEGF for a period of 2 years. It is interesting to note that although while 25-30% of eyes that have been treated show improvement, the majority of patients do not have a good response. Based on these findings, it seems that VEGF is not the only component that may be responsible for the advancement of DR. The results of the extensive randomized clinical research indicated that an average of 9 intravitreal injections of ranibizumab over the course of 2 years were not inferior to PRP. Additionally, the huge clinical trial revealed that fewer patients who got ranibizumab throughout the study period needed to have vitrectomy surgery.

The per-exam retinopathy probability was calculated by using a variety of different parameters, such as the number of lesions that were found in all four photos of each exam and the likelihood that those lesions would be found by the red and brilliant lesion detection algorithms. Therefore, each of the four photos, which were taken from both eyes, were evaluated on their own. When the results of the algorithm that evaluates image quality at the image level are combined with those of the algorithm that evaluates image quality at the exam level, two probabilities are produced at the exam level. These probabilities are the likelihood that an exam has adequate quality for assessment and the probability that an exam indicates referable retinopathy. The image quality threshold is a number that indicates when an image cannot be graded. It is a measure of how good a picture is. The sensitivity and specificity of the system may be modified to vary in comparison to the clinician's reading in a number of different ways. One way to do this is by adjusting the thresholds for red and brilliant lesions. At each setting of the threshold, the sensitivity and specificity of the whole system in relation to the clinical assessment are computed. These pairings of sensitivity and specificity are what are used to build Receiver Operator Characteristic (ROC) curves, which display the sensitivity and specificity at a number of different thresholds. An area of 1.0 on the ROC curve indicates flawless detection with sensitivity equal to specificity, while an area of 0.5 indicates the performance of a system that effectively conducts a coin flip on average. The area under the ROC curve is considered as a complete assessment of system performance. The "optimal threshold" is the point at which we subjectively determined that the sensitivity and specificity were at their best for a screening environment. This value is derived from the ROC curve.

Conclusion

Since the treatment of patients suffering from diabetes

and DR has significantly advanced over the course of the previous 50 years, an illustration of observational and clinical research may prove to be beneficial for the treatment of chronic illnesses. Despite the substantial progress that has been made, the fact that the number of people living with DR is expected to increase in the next years serves as a reminder that there is still more work to be done.

References

1. Khatri, M. Diabetes Complications. Available online: <https://www.webmd.com/diabetes/diabetes-complications> (accessed on 18 May 2022).
2. Chakrabarti R. Harper CA; Keeffe JE. Diabetic Retinopathy Management Guidelines. Expert Rev. Ophthalmol. 2012;7:417-439.
3. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs- an extension of the modified Airlie House classification. Ophthalmology. 2020;127: S99-S119.
4. Scanlon PH, Wilkinson CP, Aldington SJ, et al. A Practical Manual of Diabetic Retinopathy Management, 1st ed.; Wiley-Blackwell: Hoboken, NJ, USA. 2009;1-214.
5. Ravelo JL. Aging and Population Growth, Challenges for Vision Care: WHO Report. 2019. Available online: <https://www.devex.com/news/aging-and-population-growth-challenges-for-vision-care-who-report-95763> (accessed on 3 January 2022).
6. WHO. World Report on Vision, 2019. Available online: <https://www.who.int/publications/i/item/9789241516570> (accessed on 3 January 2022).
7. Kumar R, Pal R. India achieves WHO recommended doctor population ratio: A call for a paradigm shift in public health discourse! J. Fam. Med. Prim. Care. 2018;7:841-844. WHO. Global Data on Visual Impairment.
8. Centers for Disease Control and Prevention. Common Eye Disorders and Diseases. 2020.
9. Malik U. Most Common Eye Problems-Signs, Symptoms and Treatment Options. 2021
10. Stoitsis J, Valavanis I, Mougiakakou SG, et al. Computer aided diagnosis based on medical image processing and artificial intelligence methods. Nucl. Instrum. Methods Phys. Res. Sect. A 2006;569:591-595.
11. Mushtaq G, Siddiqui F. Detection of diabetic retinopathy using deep learning methodology. IOP Conf. Ser. Mater. Sci. Eng. 2021;1070:012049.
12. Taylor R, Batey D. Handbook of Retinal Screening in Diabetes: Diagnosis and Management. In Handbook of Retinal Screening in Diabetes: Diagnosis and Management, 2nd ed.; Wiley-Blackwell: Chichester, UK. 2012;89-103.
13. Gupta A, Chhikara R. Diabetic Retinopathy: Present

- and Past. *Procedia Comput. Sci.* 2018;132:1432-1440.
14. Ishtiaq U, Kareem SA, Abdullah ERMF, et al. Diabetic retinopathy detection through artificial intelligent techniques: A review and open issues. *Multimedia Tools Appl.* 2019;79:15209-15252.
 15. Lin J, Yu L, Weng, Q, Zheng, X. Retinal image quality assessment for diabetic retinopathy screening: A survey. *Multimedia Tools Appl.* 2020;79:16173-16199.
 16. Qureshi, I. Glaucoma Detection in Retinal Images Using Image Processing Techniques: A Survey. *Int. J. Adv. Netw. Appl.* 2015;7:2705-2718.
 17. Wang Z, Yin Y, Shi J, et al. Wang, X. Zoom-in-Net: Deep Mining Lesions for Diabetic Retinopathy Detection. In *Proceedings of the International Conference on Medical Image Computing and Computer-Assisted Intervention*, Quebec City, QC, Canada. 2017;267-275.
-